SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma, Cutaneous Malignant

Interventions

BIOLOGICAL: IMA203
BIOLOGICAL: nivolumab plus relatlimab
BIOLOGICAL: lifileucel
BIOLOGICAL: nivolumab
BIOLOGICAL: pembrolizumab
BIOLOGICAL: ipilimumab
DRUG: Dacarbazine
DRUG: temozolomide
DRUG: paclitaxel
DRUG: paclitaxel plus carboplatin
DRUG: Albumin-Bound Paclitaxel

Sponsor

Immatics US, Inc.